ScreenerHero
ELANElanco Animal Health Incorporat
NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · elanco.com
24.13USD-1.53%Mkt Cap: 12.24B $P/E: —

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vac…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap12.24B $
Enterprise Value15.47B $
Revenue (TTM)5.02B $
Gross Profit2.59B $
Net Income (TTM)-232.00M $
Revenue/Share10.09 USD
Last Price24.13 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.4K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)18.64
PEG4.04
EV/EBITDA15.37
EV/Revenue3.08
P/S2.34
P/B1.79
EPS (TTM)-0.39
EPS (Forward)1.26
52W Range
17.1165% of range27.98
52W High27.98 USD
52W Low17.11 USD
Profitability
Gross Margin54.99%
Oper. Margin8.63%
EBITDA Margin20.06%
Profit Margin-4.92%
ROE-3.54%
ROA-1.74%
Growth
Revenue Growth10.20%
Earnings Growth440.50%
Cash Flow & Leverage
Operating CF560.00M $
CapEx (TTM)276.00M $
FCF Margin16.47%
FCF Yield6.76%
Net Debt3.70B $
Net Debt/EBITDA3.68
Balance Sheet
Debt/Equity0.61
Current Ratio2.05
Quick Ratio0.91
Book Value/Sh13.19 USD
Cash/Share1.061 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)31.21 USD
Upside (mean)+29.4%
Target Range26.00 USD – 34.00 USD
$26.00+29.4% to mean$34.00
# Analysts14
Ownership
Shares Out.499.62M
Float495.12M
Insiders1.22%
Institutions115.46%
Short Interest
Short Ratio7.9d
Short % Float11.45%
Short % Out.7.21%
Shares Short36.00M
Short (prev mo.)35.22M
Technical
SMA 5024.52 (-1.6%)
SMA 20023.60 (+2.2%)
Beta1.69
S&P 52W Chg18.16%
Avg Vol (30d)5.92M
Avg Vol (10d)9.51M
Technical Indicators
RSI (14)51.5
MACD-0.4181
MACD Signal-0.3100
MACD Hist.-0.1081
BB Upper27.58 USD
BB Middle24.52 USD
BB Lower21.47 USD
BB Width24.90%
ATR (14)1.104 USD
Vol Ratio (20d)0.41x